CRISPR zaps HPV lesions in new trial – could it prevent cervical cancer?
Disease control
Recruiting now
This early study tests a single-dose CRISPR gene therapy (BD114) in 12 women aged 25–50 with high-grade cervical lesions caused by HPV-16. The goal is to see if it safely clears the abnormal cells and the virus. While promising, this is not a cure because the virus may persist or…
Phase: NA • Sponsor: Shanghai BDgene Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC